Erectile Dysfunction (ED) Drugs Market: 4.76% Y-O-Y Growth Rate in 2022 | By Product (oral drugs, topical drugs, and others) and Geography | Growth, Trends, and Forecasts (2022 - 2026)

NEW YORK, March 23, 2022 /PRNewswire/ -- The Erectile Dysfunction (ED) Drugs Market value is set to grow by USD 1.20 billion, progressing at a CAGR of 6.1% from 2021 to 2026, as per the latest report by Technavio.

Request a free sample report to know exact growth variance and the Y-O-Y growth rate 

Erectile Dysfunction (ED) Drugs Market 2022-2026: Segmentation

• Product
• Oral Drugs
• Topical Drugs
• Others

The erectile dysfunction (ED) drugs market share growth by the oral drugs segment will be significant during the forecast period. Oral drugs have the advantage of high patient compliance due to easy route of administration and high bioavailability. These drugs have been dominating the market for a long time due to the ease of administration or self-administration. Moreover, the OTC availability of these drugs is a major factor that contributes to their large market share. The oral drugs segment is expected to exhibit decelerating growth during the forecast period. Most of the leading drugs used for the treatment of ED belong to this segment. The patent expiration of these drugs is paving the way for genericization, which is responsible for the declining growth of this segment. 

• Geography
• North America
• Europe
• Asia
• Rest of World (ROW)

39% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for erectile dysfunction (ED) drugs in North America. Market growth in this region will be slower than the growth of the market in the European and Asian regions.

The increasing prevalence of chronic diseases will facilitate the erectile dysfunction (ED) drugs market growth in North America over the forecast period. 

Download FREE Sample Report for more insights on the market share & contribution of various regions & segments

Increasing Prevalence of Chronic Diseases to Boost the Market Growth

Sexual dysfunction disorders are more common in women than in men and involve loss of desire, orgasm problems, and pain during sex. The onset of sexual dysfunction disorders in women is attributed to hormonal factors, menstrual irregularities, amenorrhea, lack of vaginal lubrication, and failure to conceive. Female sexual dysfunction can be caused due to various chronic diseases such as diabetes. Globally, diabetes is one of the most common chronic diseases. Patients with diabetes may have several clinical conditions, including overweight, hypertension, obesity, metabolic syndrome, cigarette smoking, and atherogenic dyslipidemia, which are risk factors for sexual dysfunction. The rising prevalence of these conditions across the globe is expected to increase the patient pool with a large number of men and women having sexual dysfunctions, which, in turn, will drive the growth of the global ED drugs market during the forecast period.

Patent Expiry of Blockbuster Drugs to Hamper the Market Growth

The blockbuster drugs dominating the global ED drugs market have already faced or are on the verge of facing patent expiration. The key drugs in the market include VIAGRA (Pfizer), CIALIS (Eli Lilly), and LEVITRA and STAXYN (Bayer). For instance, the patents for VIAGRA expired in December 2017 in the US. To recover the losses due to patent expiration, Pfizer has entered into a patent litigation settlement with Teva Pharmaceuticals and has launched the generic version of VIAGRA in the US in December 2017. For manufacturing the generic version of a drug, there are limited legal procedures, and the production expenses are also low. Hence, the market emergence of a wide range of generic versions, which are priced lower than the branded versions, is a major challenge faced by the market.

Download Free sample Report for insights on the Drivers, Trends, and Challenges that will help companies evaluate and develop growth strategies for 2022-2026

Our Erectile Dysfunction (ED) Drugs Market Report Covers the Following Areas:

• Erectile Dysfunction (ED) Drugs Market size
• Erectile Dysfunction (ED) Drugs Market trends
• Erectile Dysfunction (ED) Drugs Market analysis

Erectile Dysfunction (ED) Drugs Market 2022-2026: Vendor Analysis

The erectile dysfunction (ED) drugs market report offers information on several market vendors, including Aurobindo Pharma Ltd., Bayer AG, Cadila Healthcare Ltd., Cipla Ltd., Dr. Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, Futura Medical plc, GlaxoSmithKline Plc, Innovcare Lifesciences Pvt. Ltd., Lupin Ltd., Pfizer Inc., SK Chemicals Co. Ltd., Teva Pharmaceutical Industries Ltd., TTK Healthcare Ltd., Viatris Inc., VIVUS Inc., and Sanzyme (P) Ltd. among others.

Moreover, the market is fragmented and the vendors are deploying growth strategies such as forming strategic alliances to increase their product offerings and geographical reach to compete in the market.

Download Our FREE Sample Report for more insights on vendors with product offerings & news

Erectile Dysfunction (ED) Drugs Market 2022-2026: Key Highlights

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will assist erectile dysfunction (ED) drugs market growth during the next five years
• Estimation of the erectile dysfunction (ED) drugs market size and its contribution to the parent market
• Predictions on upcoming trends and changes in consumer behavior
• The growth of the erectile dysfunction (ED) drugs market
• Analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of erectile dysfunction (ed) drugs market vendors

Related Reports:

Testosterone Replacement Therapy Market by Product and Geography - Forecast and Analysis: The testosterone replacement therapy market size has the potential to grow by USD 113.54 million and the market's growth momentum will decelerate during the forecast period. To get more exclusive research insights: Download Our FREE Sample Report

Sexual Enhancement Supplements Market by Product and Geography - Forecast and Analysis: The sexual enhancement supplements market size has the potential to grow by USD 407.16 million and the market's growth momentum will accelerate during the forecast period. To get more exclusive research insights: Download Our FREE Sample Report

Table of Contents:

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers
• Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026

• 4.3 Bargaining power of suppliers
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product

• 5.1 Market segments
• Exhibit 24: Chart on Product - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Product - Market share 2021-2026 (%)

• 5.2 Comparison by Product
• Exhibit 26: Chart on Comparison by Product
• Exhibit 27: Data Table on Comparison by Product

• 5.3 Oral drugs - Market size and forecast 2021-2026
• Exhibit 28: Chart on Oral drugs - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Oral drugs - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Oral drugs - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Oral drugs - Year-over-year growth 2021-2026 (%)

• 5.4 Topical drugs - Market size and forecast 2021-2026
• Exhibit 32: Chart on Topical drugs - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Topical drugs - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Topical drugs - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Topical drugs - Year-over-year growth 2021-2026 (%)

• 5.5 Others - Market size and forecast 2021-2026
• Exhibit 36: Chart on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 37: Data Table on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 38: Chart on Others - Year-over-year growth 2021-2026 (%)
• Exhibit 39: Data Table on Others - Year-over-year growth 2021-2026 (%)

• 5.6 Market opportunity by Product
• Exhibit 40: Market opportunity by Product ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview
• Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation
• Exhibit 42: Chart on Market share by geography 2021-2026 (%)
• Exhibit 43: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison
• Exhibit 44: Chart on Geographic comparison
• Exhibit 45: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 Market opportunity by geography
• Exhibit 62: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges
• Exhibit 63: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
• Exhibit 64: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption
• Exhibit 65: Overview on factors of disruption

• 9.4 Industry risks
• Exhibit 66: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 67: Vendors covered

• 10.2 Market positioning of vendors
• Exhibit 68: Matrix on vendor position and classification

• 10.3 Aurobindo Pharma Ltd.
• Exhibit 69: Aurobindo Pharma Ltd. - Overview
• Exhibit 70: Aurobindo Pharma Ltd. - Product / Service
• Exhibit 71: Aurobindo Pharma Ltd. - Key offerings

• 10.4 Bayer AG
• Exhibit 72: Bayer AG - Overview
• Exhibit 73: Bayer AG - Business segments
• Exhibit 74: Bayer AG - Key news
• Exhibit 75: Bayer AG - Key offerings
• Exhibit 76: Bayer AG - Segment focus

• 10.5 Cipla Ltd.
• Exhibit 77: Cipla Ltd. - Overview
• Exhibit 78: Cipla Ltd. - Business segments
• Exhibit 79: Cipla Ltd. - Key news
• Exhibit 80: Cipla Ltd. - Key offerings
• Exhibit 81: Cipla Ltd. - Segment focus

• 10.6 Eli Lilly and Co.
• Exhibit 82: Eli Lilly and Co. - Overview
• Exhibit 83: Eli Lilly and Co. - Business segments
• Exhibit 84: Eli Lilly and Co. - Key offerings
• Exhibit 85: Eli Lilly and Co. - Segment focus

• 10.7 Endo International Plc
• Exhibit 86: Endo International Plc - Overview
• Exhibit 87: Endo International Plc - Business segments
• Exhibit 88: Endo International Plc - Key news
• Exhibit 89: Endo International Plc - Key offerings
• Exhibit 90: Endo International Plc - Segment focus

• 10.8 Futura Medical plc
• Exhibit 91: Futura Medical plc - Overview
• Exhibit 92: Futura Medical plc - Business segments
• Exhibit 93: Futura Medical plc - Key offerings
• Exhibit 94: Futura Medical plc - Segment focus

• 10.9 GlaxoSmithKline Plc
• Exhibit 95: GlaxoSmithKline Plc - Overview
• Exhibit 96: GlaxoSmithKline Plc - Business segments
• Exhibit 97: GlaxoSmithKline Plc - Key news
• Exhibit 98: GlaxoSmithKline Plc - Key offerings
• Exhibit 99: GlaxoSmithKline Plc - Segment focus

• 10.10 Pfizer Inc.
• Exhibit 100: Pfizer Inc. - Overview
• Exhibit 101: Pfizer Inc. - Business segments
• Exhibit 102: Pfizer Inc. - Key news
• Exhibit 103: Pfizer Inc. - Key offerings
• Exhibit 104: Pfizer Inc. - Segment focus

• 10.11 Teva Pharmaceutical Industries Ltd.
• Exhibit 105: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 106: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 107: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 108: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 109: Teva Pharmaceutical Industries Ltd. - Segment focus

• 10.12 VIVUS Inc.
• Exhibit 110: VIVUS Inc. - Overview
• Exhibit 111: VIVUS Inc. - Business segments
• Exhibit 112: VIVUS Inc. - Key news
• Exhibit 113: VIVUS Inc. - Key offerings
• Exhibit 114: VIVUS Inc. - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist
• Exhibit 115: Inclusions checklist
• Exhibit 116: Exclusions checklist

• 11.3 Currency conversion rates for US$
• Exhibit 117: Currency conversion rates for US$

• 11.4 Research methodology
• Exhibit 118: Research methodology
• Exhibit 119: Validation techniques employed for market sizing
• Exhibit 120: Information sources

• 11.5 List of abbreviations
• Exhibit 121: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED